[go: up one dir, main page]

WO2001077095A3 - Derivatives of alpha-mercaptoacetamide - Google Patents

Derivatives of alpha-mercaptoacetamide Download PDF

Info

Publication number
WO2001077095A3
WO2001077095A3 PCT/EP2001/003848 EP0103848W WO0177095A3 WO 2001077095 A3 WO2001077095 A3 WO 2001077095A3 EP 0103848 W EP0103848 W EP 0103848W WO 0177095 A3 WO0177095 A3 WO 0177095A3
Authority
WO
WIPO (PCT)
Prior art keywords
derivatives
mercaptoacetamide
alpha
compounds
meanings
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2001/003848
Other languages
French (fr)
Other versions
WO2001077095A2 (en
Inventor
Lombaert Stephane De
Fariborz Firooznia
Denton Wade Hoyer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis Pharma GmbH Austria
Novartis AG
Original Assignee
Novartis Erfindungen Verwaltungs GmbH
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Erfindungen Verwaltungs GmbH, Novartis AG filed Critical Novartis Erfindungen Verwaltungs GmbH
Priority to AU2001254776A priority Critical patent/AU2001254776A1/en
Publication of WO2001077095A2 publication Critical patent/WO2001077095A2/en
Publication of WO2001077095A3 publication Critical patent/WO2001077095A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/91—Dibenzofurans; Hydrogenated dibenzofurans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06078—Dipeptides with the first amino acid being neutral and aromatic or cycloaliphatic

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Novel thiol derivatives of formula (I) wherein variables R1, R2, R3, R4, A, X, and Y have the meanings as defined hereinbefore; disulfide derivatives derived from said compounds wherein R1 is hydrogen; and pharmaceutically acceptable salts thereof; said compounds being useful as endothelin converting enzyme inhibitors.
PCT/EP2001/003848 2000-04-06 2001-04-04 Derivatives of alpha-mercaptoacetamide Ceased WO2001077095A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2001254776A AU2001254776A1 (en) 2000-04-06 2001-04-04 Organic compounds

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US19501100P 2000-04-06 2000-04-06
US60/195,011 2000-04-06

Publications (2)

Publication Number Publication Date
WO2001077095A2 WO2001077095A2 (en) 2001-10-18
WO2001077095A3 true WO2001077095A3 (en) 2002-06-27

Family

ID=22719711

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2001/003848 Ceased WO2001077095A2 (en) 2000-04-06 2001-04-04 Derivatives of alpha-mercaptoacetamide

Country Status (2)

Country Link
AU (1) AU2001254776A1 (en)
WO (1) WO2001077095A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR0212899A (en) 2001-09-21 2004-11-03 Novartis Ag Organic compounds

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999055726A1 (en) * 1998-04-23 1999-11-04 Novartis Ag Certain thiol inhibitors of endothelin-converting enzyme

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999055726A1 (en) * 1998-04-23 1999-11-04 Novartis Ag Certain thiol inhibitors of endothelin-converting enzyme

Also Published As

Publication number Publication date
AU2001254776A1 (en) 2001-10-23
WO2001077095A2 (en) 2001-10-18

Similar Documents

Publication Publication Date Title
CA2379747A1 (en) Novel succinate derivative compounds useful as cysteine protease inhibitors
EP0931788A3 (en) Metalloprotease inhibitors
AU2003297291A1 (en) Substituted arylcyclopropylacetamides as glucokinase activators
WO2004014913A3 (en) Derivatives of 2-trifluormethyl-6-aminopurine as phosphodiesterase 4 inhibitors
MY136141A (en) Novel hydantoin derivatives and pharmaceutical compositions useful as metalloproteinase inhibitors
AU2002211216A1 (en) Substituted aminopropoxyaryl derivatives useful as agonists for lxr
EP0513387A4 (en) Active oxygen inhibitor
MY138525A (en) Substituted acid derivatives useful as antidiabetic and antiobesity agents and method
NZ329532A (en) Diazepino-indoles as phosphodiesterase iv inhibitors
WO2002044153A8 (en) 4-6-diphenyl pyridine derivatives as antiinflammatory agents
PH12009500610A1 (en) 4-imidazolin-2-one compounds
AU2003257493A1 (en) Pleuromutilin derivatives as antimicrobbials
WO1999000373A8 (en) Benzimidazole derivatives
AU2001276808A1 (en) A crystalline form of celecoxib
EP1709037B8 (en) Hiv protease inhibiting sulfonamides
AU4250200A (en) Ppar-(gamma) agonists as agents for the treatment of type ii diabetes
WO2004035800A3 (en) Intermediate cefdinir salts
WO2003004497A1 (en) Novel heterocyclic compound
TR200201128T2 (en) Tetrahydrothiopyraniphalazinone derivatives as PDE4 inhibitors.
WO2004043349A3 (en) Isoxazoline derivatives as inhibitors of matrix metalloproteinases and/or tnf-alpha converting enzyme
CA2309474A1 (en) New 4-arylpiperidine derivatives for the treatment of pruritus
IL138688A0 (en) Certain heteroaryl substituted thiol inhibitors of endothelin-converting enzyme
EP1555261A4 (en) Valerolactone compounds and perfume composition
WO2004030664A3 (en) New compounds for the inhibition of undesired cell proliferation and use thereof
EP1291341A4 (en) Compounds exhibiting thrombopoietin-like activities

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP